MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

2026-03-06 - 21:23

AUSTIN, Texas -- MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell LlamaTM, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies. Bispecific antibody sales alone are projected to reach US$50 billion by 2030, with the broader cell therapy market adding tens of billions more. B Cell LlamaTM is designed to help partners capture this opportunity with better starting material and AI-guided precision at every step of the discovery process. Read More